Medical professionals reviewing screenings on two computer monitors

Today's standard of care was yesterday's clinical trial. Consider clinical research.

University of Maryland St. Joseph Medical Center's (UM SJMC) Cancer Institute is an active partner in advancing the understanding and treatment of cancer through clinical trials and research studies of people who have cancer. The goal of these studies is to find better ways to treat, diagnose and prevent cancer so that people can live better and longer.

Clinical trials are the engine of cancer research and can represent a patient's best chance for effective therapy. The clinical trials offered at UM St. Joseph Medical Center include preventive, treatment and observational research studies. They are based on nationally approved standards of cancer care and are designed to research how we can best improve our patients' cancer outcomes.

Patients have access to national, investigator-initiated and industry-sponsored clinical trials. The UM SJMC research team can help determine if a treatment option is right for a particular patient. As with all clinical trials, patients who enroll must meet specific criteria. Clinical trials currently in process at UM SJMC's Cancer Institute are below.

"There are many great reasons to be part of a clinical trial," says Kimberly Schlesinger, MD, medical director of the Cancer Institute at UM St. Joseph Medical Center. "If you think a clinical trial may be right for you, talk to your doctor to learn more or visit clinicaltrials.gov."

Advanced Cancers

Breast Cancer

  • TOL2506A – Ovelia: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
    Patients in this study have been diagnosed with HR+, HER2-negative breast cancer while still being in a premenopausal hormone status (i.e., females with active ovaries that produce hormones that cause menstrual cycles, even if they are not regular). This is a phase III study to evaluate the effectiveness of a three-month course of leuprolide acetate for injectable suspension in combination with endocrine therapy to suppress ovarian function in these patients.
  • A191901 – Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions – This study may help determine if using supportive text message reminders and/or telephone-based counseling can help encourage women to take their endocrine therapy medication as prescribed. Good medication adherence—or how well patients take the medication as directed by their doctors—may contribute to better health outcomes. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor-positive breast cancer patients.

  • B-61 – A Phase III, Randomized, Open-Label, Multi-Center Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer. Endocrine therapy with tamoxifen or aromatase inhibitors (AIs [with or without ovarian function suppression (OFS)]) are currently the main endocrine treatment options for estrogen receptor-positive (ER+) early breast cancer (EBC). Despite the effectiveness of available therapies, many patients ultimately experience disease relapse or develop resistance to these agents. In addition, treatment-associated toxicity is an important major barrier to the full application of the current cancer treatment leading to treatment discontinuation in many patients. Consequently, there is a critical need for more optimal adjuvant therapy in patients with ER+ EBC, particularly for patients who have a high likelihood of recurrence.

Colorectal Cancer

Lung Cancer

Pancreatic Cancer

  • A021806 – Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer – This study compares the effectiveness of chemotherapy given before and after surgery versus chemotherapy given after surgery for the treatment of pancreatic cancer that can be removed by surgery. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly) only.

    image of someone holding a vile that is labeled platelet count

Studies Currently in Active Follow-up

Please note: These studies are currently full and in active follow-up at UM St. Joseph. At this time, we are actively tracking study participants' progress and using what we learn to offer even safer, more effective and advanced treatment options for our patients.

Breast Cancer

Lymphoma

  • RELEVANCE: Combined Rituximab and Lenalidomide Treatment for Untreated Patients with Follicular Lymphoma – Patients in this study have been diagnosed with follicular lymphoma (FL), which is a cancer of lymphocytes, a type of white blood cell. Recent studies suggest that rituximab plus chemotherapy followed by rituximab maintenance therapy is becoming a new standard of care for FL patients. This study involves the need to look for new treatments that may reduce the risk for recurrence or to prolong the disease-free time frame.

For more information about clinical trials at UM St. Joseph Medical Center and to learn more about how we can help patients access these important medical studies, please call our Office of Clinical Research at 410-427-2571.